Introduction: Metformin is recommended as first-line treatment for type 2 diabetes (T2D) by
all major diabetes guidelines. With appropriate usage it is safe and effective overall, but its …

Despite its widespread use as the first-line agent for the treatment of type 2 diabetes, it has
become clear that metformin does not work optimally for everyone. Elucidating who are the …

Most FDA‐approved drugs are not equally effective in all patients, suggesting that
identification of biomarkers to predict responders to a chemoprevention agent will be …

Metformin is the first-line pharmacotherapy for managing type 2 diabetes (T2D). However,
many patients with T2D do not respond to or tolerate metformin well. Currently, there are no …

OBJECTIVE Genome-wide association studies have begun to elucidate the genetic
architecture of type 2 diabetes. We examined whether single nucleotide polymorphisms …

The incidence of type 2 diabetes (T2D) and its costs to the health care system continue to
rise. Despite the availability of at least 10 drug classes for the treatment of T2D, metformin …

Background Metformin has been widely used to alleviate hyperglycemia in patients with type
2 diabetes mainly via suppressing hepatic gluconeogenesis. However, the underlying …

Genome-wide significant loci for metformin response in type 2 diabetes reported elsewhere
have not been replicated in the Diabetes Prevention Program (DPP). To assess …

Objective Genome-wide association studies have uncovered a large number of genetic
variants associated with type 2 diabetes or related phenotypes. In many cases the causal …

Adipose differentiation and excessive lipid accumulation are the important characteristics of
obesity. Metformin, as a classic hypoglycaemic drug, has been proved to reduce body …